Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole Adjunct for Weight Reduction in Schizophrenia
NCT02949752Phase 4Completed
- Sponsor
- Institute of Mental Health
- Start
- Aug 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of aripiprazole in antipsychotic-induced weight gain (AIWG), metabolic syndrome, sponsored by Institute of Mental Health. Started Aug 2016; status: completed.
02
Drugs
aripiprazole
03
Conditions
antipsychotic-induced weight gain (AIWG)metabolic syndrome
Beyond the preview
Go deeper on NCT02949752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02949752.